Key result
Guideline implementation increases quadruple GDMT use in HFrEF by ~3% at six months.
Why the study?
Evidence on real-world uptake of the contemporary four-pillar guideline-directed medical therapy strategy for HFrEF was limited.
Observational (n=3,201)
Yes
Real-world data demonstrates high persistence of quadruple guideline-directed medical therapy in HFrEF patients at 6 months, but highlights a significant ongoing gap in dose up-titration.
Real-world quadruple GDMT persistence remains high in HFrEF; extends implementation data but leaves dose titration gaps open.
Aims The BRING-UP 3 Heart Failure (HF) study was designed to the real-world implementation of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), given the limited evidence on the uptake of the contemporary four-pillar treatment strategy. Methods BRING-UP 3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites. This analysis includes HFrEF patients enrolled in the ambulatory and hospitalized cohorts with complete pharmacological data at 6-month follow-up. The objective was to describe the use of the four GDMT pillars after 6 months. Results Among 3,201 HFrEF patients enrolled, 142 (4.4%) had died by 6 months, and treatment data were available for 2950 patients. Mean age was 69±11 years (26.6% >75 years), 18.0% were female. Prescription rates of GDMT were high at baseline and remained stable over 6-months, with a shift from ACE-I/ARBs to ARNIs, and a modest increase in SGLT2i use. A significant reduction in diuretic prescription was also observed. Quadruple therapy was prescribed in 64.3% of patients at 6 months versus 63.9% at baseline/discharge (p=NS), while quadruple therapy including ARNI went from 52.9% to 55.9%, p <0.0001. Dose up-titration of GDMT remained suboptimal, with most agents prescribed at <50% of target doses. Discontinuation rates at follow-up were very low. Conclusions In this large nationwide cohort, guideline-directed therapies for HFrEF were widely implemented and maintained over 6 months with excellent treatment persistence. However, dose optimization remains a key unmet need in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Oliva et al. (2026) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=3,201). Guideline-directed medical therapy (GDMT) vs. Baseline/discharge was evaluated on Use of the four GDMT pillars (quadruple therapy) (p=NS). Quadruple guideline-directed medical therapy was prescribed in 64.3% of HFrEF patients at 6 months versus 63.9% at baseline (p=NS), though dose up-titration remained suboptimal.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: